Abstract Despite substantial advances in targeted therapeutic regimens for breast cancer (BC), clinical management remains challenging for refractory and therapy-resistant cases, especially for molecular subtypes lacking validated actionable targets. Here, we identified that FK506-binding protein 10 (FKBP10), a peptidyl-proline isomerases, was strikingly elevated in BC tissues and potentiated the malignant behaviors of BC cells in vitro and in vivo.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile